Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by sobadatthison Apr 02, 2018 3:13pm

143 Views

Post# 27816317

RE:We are

Edcando wrote: Holding up very well against the market in general. It is a true testament to what ATE has to offer the market. It would be particularly exciting to get some news /a halt while the market is doing so poorly. Investors are hungry for any green sp and it could really start a frenzy shooting this far past what it would normally have gone on its own. Beep beep beep back the truck up

I agree reed I could really use an ATE partnership or buyout right about now. 4 dollars would be enough for me lol

Bullboard Posts

Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35 billion